Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles